同期放化疗联合尼妥珠单抗治疗头颈部肿瘤的有效性  

Effectiveness of concurrent chemoradiotherapy combined with Nimotuzumab in the treatment of head and neck tumors

作　　者：毛进星[1] 曾志坚[1] 唐慧妍 余健[1] MAO Jinxing;ZENG Zhijian;TANG Huiyan;YU Jian(Department of Oncology,the First People's Hospital of Zhaoqing City,Guangdong,Zhaoqing 526000,China)

机构地区：[1]广东省肇庆市第一人民医院肿瘤科,广东肇庆526000

出　　处：《中国医药科学》2020年第4期254-256,272,共4页China Medicine And Pharmacy

摘　　要：目的探究同期放化疗联合尼妥珠单抗治疗头颈部肿瘤的有效性。方法将80例2018年1~12月我院确诊为头颈部肿瘤的患者按照随机数字表法分为对照组和观察组各40例,所有患者均实施诱导化疗,对照组采用顺铂同期放化疗,观察组联合尼妥珠单抗治疗,比较分析两组患者的临床疗效、mDFS、1年生存率及不良反应发生率。结果观察组患者治疗总有效率(85.00%)明显高于对照组(65.00%),差异有统计学意义(P <0.05)。观察组患者mDFS(13.7个月)明显高于对照组(7.3个月),差异有统计学意义(P <0.05)。两组患者1年生存率及不良反应总发生率比较差异均无统计学意义(P> 0.05)。结论同期放化疗联合尼妥珠单抗治疗头颈部肿瘤具有良好的临床疗效,患者RR、mDFS及1年生存率相较诱导化疗后单纯同期放疗更高,且不良反应发生率也未因使用尼妥珠单抗而增加,值得在临床推广应用。Objective To investigate the effectiveness of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of head and neck tumors. Methods 80 patients with head and neck tumors diagnosed in our hospital from January to December 2018 were randomly divided into control group and observation group according to the random number table method,with 40 cases in each group.All patients were treated with induction chemotherapy.The control group received concurrent chemotherapy with cisplatin,and the observation group received combined treatment with nimotuzumab.The clinical efficacy,mDFS,1-year survival rate,and incidence of adverse reactions were compared between the two groups Results The total effective rate of treatment in the observation group(85.00%)was significantly higher than that in the control group(65.00%),and the difference was statistically significant(P < 0.05).The mDFS(13.7 months)in the observation group was significantly higher than that in the control group(7.3 months),and the difference was statistically significant(P < 0.05).There was no significant difference in 1-year survival rate and the overall incidence of adverse reactions between the two groups(P > 0.05). Conclusion Concurrent chemoradiotherapy combined with Nimotuzumab in the treatment of head and neck tumors shows good clinical efficacy.The RR,mDFS and 1-year survival rate of patients are higher than those of induction chemotherapy alone after induction chemotherapy,and the incidence of adverse reactions does not increase due to the use of nimotuzumab,which is worthy of clinical application.

关 键 词：头颈部肿瘤 同期放化疗 尼妥珠单抗 总有效率 

分 类 号：R246.5[医药卫生—针灸推拿学]